Publication Strategy. The Parties shall coordinate worldwide publication strategy involving Collaboration Products and activities involving Collaboration Products related to scientific conferences through the JSC. Review and approval of individual manuscripts shall be delegated to appropriate working groups of the Parties. Each Party shall be afforded the opportunity to review and approve any scientific paper or presentation with respect to any Collaboration Product proposed for publication, presentation or distribution by the other Party or its Affiliates or Sublicensees and shall have no more than [**] to complete such review and approval (or such shorter period as may reasonably be required by applicable publication deadlines promptly communicated to such Party). The Party proposing a publication or presentation shall (a) not unreasonably reject comments furnished by the other Party, (b) comply with the other Party’s request to delete references to its Confidential Information in any such publication or presentation and (c) delay publication for such reasonable period requested by the other Party to permit the filing of patent applications concerning any AstraZeneca Technology, Xxxxxxxxx Technology or Joint Technology disclosed in material proposed for such publication or presentation. In no event will Confidential Information of a Party be published without the consent of such Party.
Publication Strategy. If either Party, or any of their respective Affiliates or sublicensees (each, a “Proposing Party”), proposes the publication, presentation or distribution of any scientific paper or presentation (i) with respect to any Product, or (ii) which otherwise may reasonably contain Know-How or other Intellectual Property of the other Party, then the Licensee (if the Proposing Party is XENCOR or its Affiliate or sublicensee) or XENCOR (if the Proposing Party is Licensee or its Affiliate or Sublicensee) shall be afforded the opportunity to review and approve such scientific paper or presentation and shall have no less than [***] to complete such review and approval (or such shorter period as may reasonably be required by applicable publication deadlines promptly communicated to the reviewing Party). The Proposing Party shall (a) not unreasonably reject comments furnished by the reviewing Party; (b) comply with the reviewing Party’s request to delete references to its Confidential Information in any such publication or presentation; and (c) delay publication for such reasonable period requested by the reviewing Party to permit the filing of patent applications concerning any XENCOR Intellectual Property, Licensee Intellectual Property or Joint Intellectual Property disclosed in material proposed for such publication or presentation. For the avoidance of doubt, in no event will Confidential Information of a Party be published without the written consent of such Party.
Publication Strategy. Subject to Ironwood’s obligations to coordinate worldwide publication strategy with Forest under the Forest Agreement, the Parties will coordinate worldwide publication strategy involving the Product and activities involving the Product related to scientific conferences inside and outside the Territory, including through delegation to appropriate working groups of the Parties. The Parties intend that the provisions of this Section 3.6 apply to the Parties and their respective Affiliates, licensees and Sublicensees. For the avoidance of doubt, no Sublicensee will be permitted to publish or present materials regarding the Product, and any sublicense agreement hereunder will contain a provision prohibiting such activities.
Publication Strategy. Any and all publications, totally or partially, of the Product Development Information, including but not limited to clinical studies results, shall be agreed in advance by the Parties through a decision passed by the JSC.
Publication Strategy. The JSC shall develop and approve a global publication strategy for the Development activities related to the Licensed Products in the Field (the “Publication Strategy”) that is consistent with the Development Plan and the Parties’ applicable internal policies. The JSC may also from time to time develop and approve substantive amendments to such Publication Strategy and, upon approval by the JSC of any such amendment, the Publication Strategy shall be amended accordingly.
Publication Strategy. Subject to Ironwood’s obligations to coordinate worldwide publication strategy with Forest under the Forest Agreement and with Almirall under the Almirall Agreement, Astellas will coordinate with Ironwood (i) its publication strategy involving the Product and (ii) activities involving the Product related to scientific conferences and other presentations. The Parties intend that the provisions of this Section 3.6 apply to Astellas and its Affiliates, licensees and Sublicensees. For the avoidance of [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. doubt, no Sublicensee will be permitted to publish or present materials regarding the Product, and any Sublicense agreement hereunder will contain a provision prohibiting such activities.
Publication Strategy. The JSC shall develop a strategy for reviewing, coordinating and releasing publications including results of studies conducted for the Product by or on behalf of either Party. Each Party would submit any proposed publications to the other Party for review and comment as provided in Section 14.6.
Publication Strategy. The Parties shall coordinate worldwide publication strategy involving Products and activities involving Products related to scientific conferences inside and outside the Territory. Each Party shall be afforded the opportunity to review and approve any scientific paper or presentation with respect to any Product proposed for publication, presentation or distribution by the other Party or its Affiliates, licensees or Sublicensees and shall have [***] days to complete such review and approval (or such shorter period as may reasonably be required by applicable publication deadlines promptly communicated to such Party). The Party proposing publication or presentation shall (i) not unreasonably reject comments furnished by the other Party; (ii) comply with the other Party’s Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Publication Strategy. The JCC shall agree upon a global plan for publishing, presenting and disclosing publicly important Program Data and other key results achieved in connection with the Development and Commercialization of the Product (the “Publication Plan”), with the goals of protecting the Parties’ ability to obtain patents and other intellectual property protection with respect to such activities, as applicable, to support each Party’s financing and business objectives, and to position the Product for Regulatory Approval and successful Commercialization in the Field in the Territory. The JCC shall review and approve the Publication Plan. The Publication Strategy may be updated from time to time, subject to review and approval of the JCC. The Parties shall comply with the Publication Strategy in publicly approved by the JCC. If the JCC cannot agree on a particular press release, publication, presentation, or other public disclosure regarding Program Data, then a Party can decide for itself for its Licensed Territories, subject to Section 10.5.2 (Press Release, Publication and Presentation Process) and the other obligations of this Agreement.
Publication Strategy. Within [***] of the Effective Date, the JDC will prepare a global publication strategy for the Development activities related to the Licensed Antibodies and Licensed Products Developed under the Development Program (the “Publication Strategy”) that is consistent with the Global Development Plan and any Additional Development Proposal; provided that unless otherwise agreed by the Parties, the Publication Strategy will contemplate that, as between the Parties, GSK will be primarily responsible for scientific publications related to Clinical Trials sponsored by GSK and ITEOS will be primarily responsible for scientific publications related to the Clinical Trials sponsored by ITEOS. The JDC (with consultation from the Patent Liaisons, where applicable) will review and approve such Publication Strategy, and may amend it from time to time upon agreement of the Parties. The Parties shall have no right to publish in relation to any Development activities conducted hereunder other than as specified in the Publication Strategy or otherwise in this Section 10.8.1 (Publication Strategy); provided that either Party shall have the right to re-publish (in accordance with 10.8.4 (Re-Publication) below) or reference any publication (or information therein) previously published in accordance with the Publication Strategy and any publication (or information therein) published prior to the Execution Date. If a Party or its employees or consultants (such as clinical investigators) desires to make a publication relating to a Clinical Trial for a Licensed Product that is being conducted under the Global Development Plan or that otherwise relates to the Licensed Antibodies or Licensed Products or the activities conducted hereunder, then it shall make such request to the other Party through the JDC, and such publication shall be subject to review under Section 10.8.2 (Review by the Parties), and the consent of such other Party, which shall not be unreasonably withheld.
